CannBioRx Life Sciences Corp Stock News

PALO ALTO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the deve

The stock price of 180 Life Sciences Corp (NASDAQ: ATNF) increased by over 11% pre-market today. This is why it happened.

PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the deve

PALO ALTO, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the develo

180 Life Sciences Corp. (NASDAQ:ATNF) with the stream of 10.35% also noticed, India Senseonics Holdings, Inc. (AMEX:SENS) encountered a rapid change of 5.43% in the last hour of Fridays trading The post Bright Stock Buzz: 180 Life Sciences Corp. (NASDAQ:ATNF), Senseonics Holdings, Inc. (AMEX:SENS) appeared first on Stocks Equity .

180 Life Sciences Corp. (NASDAQ:ATNF) COO Quan Anh Vu acquired 8,000 shares of the companys stock in a transaction dated Thursday, December 16th. The shares were bought at an average cost of $3.98 per share, with a total value of $31,840.00. The acquisition was disclosed in a document filed with the SEC, which is accessible []

PALO ALTO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the deve

PALO ALTO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into a new, exclusive global licensing agreement with The University of Oxford (Oxford) for the development and commercialization of HMGB1, a regenerative molecule for promoting liver repair and regeneration. Under the terms of the transaction, the Company will pay Oxford a small one-time upfront license fee, which will have an insignificant impact on the 2022 expenditure rate; and any further payments are contingent upon the achievement of certain clinical, regulatory and sales milestones.

180 Life Sciences Corp. (NASDAQ:ATNF) CEO James N. Woody purchased 12,500 shares of the firms stock in a transaction dated Thursday, December 9th. The stock was acquired at an average price of $4.27 per share, with a total value of $53,375.00. The acquisition was disclosed in a filing with the SEC, which can be accessed []

180 Life Sciences Corp. (NASDAQ:ATNF) COO Quan Anh Vu bought 4,500 shares of the firms stock in a transaction that occurred on Friday, December 10th. The stock was bought at an average price of $3.90 per share, for a total transaction of $17,550.00. The transaction was disclosed in a legal filing with the Securities & []

Related Stocks: ATNF ,

You can buy these penny stocks for under $5 but are they worth the risk? The post 4 Penny Stocks To Buy For Under $5 Before 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

180 Life Sciences Corp. (NASDAQ:ATNF) Director Jr. Donald A. Mcgovern bought 25,000 shares of the businesss stock in a transaction dated Thursday, December 9th. The stock was acquired at an average cost of $4.13 per share, for a total transaction of $103,250.00. The purchase was disclosed in a filing with the SEC, which is accessible []

You can buy these penny stocks for under $5 but are they worth the risk? The post 4 Penny Stocks To Buy For Under $5 Before 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the deve